Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of LY3114062 in Inflammatory Arthritis
NCT02144272Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Primary completion
- May 2015
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of LY3114062 in inflammatory arthritis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Drug-Related Adverse Events at 3 months. Started Jun 2014; status: completed.
02
Drugs
LY3114062
03
Conditions
inflammatory arthritis
Beyond the preview
Go deeper on NCT02144272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144272.